Clinical Trial

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, randomized, two-cohort clinical trial to evaluate the efficacy and safety of SHR-1701 with or without apatinib in combined with chemotherapy of neoadjuvant treatment for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-17
Trial Details
NCT Number NCT07464756
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Gastric Adenocarcinoma
Enrollment 80 participants
Start Date 2026-04-03
Primary Completion 2028-05-31 (estimated)
Study Completion 2030-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-16